Time to Scalp Hair, Eyebrow, and Eyelash Improvement in Patients with Alopecia Areata Treated with Baricitinib in the Phase 2 Portion of the Phase 2/3 BRAVE-AA1 Study

    August 2021 in “ Journal of The American Academy of Dermatology ”
    Maryanne M. Senna, Amy J. McMichael, Tiffany T. Mayo, Julian Mackay‐Wiggan, Marc Glashofer, Luna Sun, Guanglei Yu, Fabio P. Nunes, Jill Shwed McCollam, Wen‐Chi Wu, Brett King
    From the encyclopedia
    Baricitinib →

    JAK inhibitor that reduces inflammation and immune attacks on hair follicles, leading to potential hair regrowth, especially in alopecia areata cases

    Alopecia Areata →

    autoimmune disorder causing patchy hair loss

    Image
    Studysummary In this study, baricitinib treatment led to significant regrowth of scalp, eyebrow, and eyelash hair in alopecia areata patients compared to placebo, with higher effectiveness seen at the 4-mg dose. Our plain-language summary of this paper — not a Tressless recommendation.
    The phase 2 of the BRAVE-AA1 study evaluated the effectiveness of baricitinib, a JAK1/JAK2 inhibitor, in treating alopecia areata (AA) patients. The study involved 82 participants divided into three groups: baricitinib 4-mg (27 participants), baricitinib 2-mg (27 participants), and placebo (28 participants). At week 36, 52% of the 4-mg group, 33% of the 2-mg group, and 4% of the placebo group achieved a Severity of Alopecia Tool (SALT) score ≤20, indicating hair regrowth. In terms of eyebrow and eyelash improvement, 39% and 60% of the 4-mg group, 29% and 40% of the 2-mg group, and 4% and 6% of the placebo group achieved eyebrow and eyelash scores ≤1, respectively. These results suggest that baricitinib may be an effective treatment for AA.
    Discuss this study in the Community →